Hair Improvement in <scp>SPINK5</scp> ‐ <scp>sEDD</scp> (Netherton Syndrome) With Dupilumab

SPINK5-syndromic epidermal differentiation disorder (sEDD) (formerly known as Netherton syndrome) is a rare genodermatosis characterized by ichthyosis linearis circumflexa, atopic diathesis, and trichorrhexis invaginata. We report an 11-year-old girl with SPINK5-sEDD who experienced marked improvement in hair density, texture, and pruritus following dupilumab. The early and sustained hair response suggests that IL-4/IL-13 blockade may modulate the perifollicular inflammatory environment and enhance follicular function. This observation supports emerging evidence that dupilumab may confer hair benefits in SPINK5-sEDD and underscores the need for systematic evaluation of this effect.